![](https://www.ronoma-pharma.com/wp-content/uploads/2024/03/Logo_Ministere.png)
![](https://www.ronoma-pharma.com/wp-content/uploads/2024/03/Logo_NormandieIncubation.png)
![](https://www.ronoma-pharma.com/wp-content/uploads/2024/03/Logo_Europe.png)
![](https://www.ronoma-pharma.com/wp-content/uploads/2024/02/cermn-logo.jpg)
![](https://www.ronoma-pharma.com/wp-content/uploads/2024/02/logo-region.png)
![](https://www.ronoma-pharma.com/wp-content/uploads/2024/02/normandieuniversite_logo_NOIR_ok-1-1.png)
![](https://www.ronoma-pharma.com/wp-content/uploads/2024/02/logo-bpi.png)
![](https://www.ronoma-pharma.com/wp-content/uploads/2019/11/unicaen.png)
![](https://www.ronoma-pharma.com/wp-content/uploads/2019/11/4G5WD24ECkWZKslHJgDidFOXN1uiRp.jpg)
![Image](https://www.ronoma-pharma.com/wp-content/uploads/2020/01/single-first-image-1.jpg)
RONOMA PROJECT
Drug Candidate Neocoprid
The company RonomA, a biotechnology company born from research in Normandy, aims to bring to market an innovative treatment for neurodegenerative diseases
- Activation of serotonergic receptors
- Acetylcholinesterase inhibition
WHO ARE WE
Our Team
Coopération impliquant Romain Legrand, qui est à la fois le fondateur et le directeur de l'entreprise, ainsi que Patrick Dallemagne et Christophe Rochais. Ces derniers, co-fondateurs et distingués enseignants-chercheurs en chimie médicale, sont affiliés au Centre d'Études et de Recherche sur le Médicament de Normandie (CERMN) à l'Université de Caen Normandie.
![Image](https://www.ronoma-pharma.com/wp-content/uploads/2020/01/single-image11.jpg)